Research and Markets: Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2012

Tue Feb 5, 2013 4:32am EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130205:nBw055827a

DUBLIN--(Business Wire)--

Research and Markets

(http://www.researchandmarkets.com/research/cvh6jj/juvenile_macular) has
announced the addition of Global Markets Direct's new report "Juvenile Macular
Degeneration (Stargardt Disease) - Pipeline Review, H2 2012" to their offering. 

Global Markets Direct's, 'Juvenile Macular Degeneration (Stargardt Disease) -
Pipeline Review, H2 2012', provides an overview of the indication's therapeutic
pipeline. This report provides information on the therapeutic development for
Juvenile Macular Degeneration (Stargardt Disease), complete with latest updates,
and special features on late-stage and discontinued projects. 

It also reviews key players involved in the therapeutic development for Juvenile
Macular Degeneration (Stargardt Disease). Juvenile Macular Degeneration
(Stargardt Disease) - Pipeline Review, Half Year is built using data and
information sourced from Global Markets Direct's proprietary databases,
Company/University websites, SEC filings, investor presentations and featured
press releases from company/university sites and industry-specific third party
sources, put together by Global Markets Direct's team. 

Scope 

- A snapshot of the global therapeutic scenario for Juvenile Macular
Degeneration (Stargardt Disease). 

- A review of the Juvenile Macular Degeneration (Stargardt Disease) products
under development by companies and universities/research institutes based on
information derived from company and industry-specific sources. 

- Coverage of products based on various stages of development ranging from
discovery till registration stages. 

- A feature on pipeline projects on the basis of monotherapy and combined
therapeutics. 

- Coverage of the Juvenile Macular Degeneration (Stargardt Disease) pipeline on
the basis of route of administration and molecule type. 

- Key discontinued pipeline projects. 

- Latest news and deals relating to the products. 

Reasons to buy 

- Identify and understand important and diverse types of therapeutics under
development for Juvenile Macular Degeneration (Stargardt Disease). 

- Identify emerging players with potentially strong product portfolio and design
effective counter-strategies to gain competitive advantage. 

- Plan mergers and acquisitions effectively by identifying players of the most
promising pipeline. 

- Devise corrective measures for pipeline projects by understanding Juvenile
Macular Degeneration (Stargardt Disease) pipeline depth and focus of Indication
therapeutics. 

- Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline. 

For more information visit
http://www.researchandmarkets.com/research/cvh6jj/juvenile_macular

Source: Global Markets Direct

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Copyright Business Wire 2013